In the present study, KLC2-WT and R312W/L523I MT bound with SMAD2 and SMAD2/3 signaling were activated upon treatment with either imatinib or TGF-β in the transformed CML cells. This evidence concerns the gene SMAD2 and chronic myelogenous leukemia, BCR-ABL1 positive.